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Abstract
BACKGROUND: It is important to use outcome measures for 
novel interventions in Alzheimer’s disease (AD) that capture 
the research participants’ views of effectiveness. The electronic 
Person-Specific Outcome Measure (ePSOM) development 
programme is underpinned by the need to identify and detect 
change in early disease manifestations and the possibilities of 
incorporating artificial intelligence in outcome measures. 
OBJECTIVES: The aim of the ePSOM programme is to 
better understand what outcomes matter to patients in the 
AD population with a focus on those at the pre-dementia 
stages of disease. Ultimately, we aim to develop an app with 
robust psychometric properties to be used as a patient reported 
outcome measure in AD clinical trials.
DESIGN: We designed and ran a nationwide study (Aug 2019 
– Nov 2019, UK), collecting primarily free text responses in 
five pre-defined domains. We collected self-reported clinical 
details and sociodemographic data to analyse responses by 
key variables whilst keeping the survey short (around 15 
minutes). We used clustering and Natural Language Processing 
techniques to identify themes which matter most to individuals 
when developing new treatments for AD.
RESULTS: The study was completed by 5,808 respondents, 
yielding over 80,000 free text answers. The analysis resulted 
in 184 themes of importance. An analysis focusing on key 
demographics to explore how priorities differed by age, gender 
and education revealed that there are significant differences in 
what groups consider important about their brain health.
DISCUSSION: The ePSOM data has generated evidence on 
what matters to people when developing new treatments for 
AD that target secondary prevention and therein maintenance 
of brain health. These results will form the basis for an electronic 
outcome measure to be used in AD clinical research and clinical 
practice.
Key words: Clinically meaningful change, electronic patient reported 
outcome measures, Alzheimer’s disease, outcome measures, brain 
health.
Introduction
Attempts to develop disease modifying therapies for Alzheimer ’s disease (AD) started over 20 years ago with little success to date. A 
recent estimate of the costs of AD was US$818B, which 
is equivalent to the combined GDP of Indonesia, The 
Netherlands, and Turkey (1).  
The lack of progress in finding a pharmacological 
treatment for AD is however at odds with a rapid 
development in the understanding of the pathology of 
AD suggesting that clinical trial design and delivery may 
partially account for a lack of progress with insensitive 
outcome measures lacking clinical meaningfulness 
also playing a part in this lack of progress. It has been 
shown that the disease process starts long before an 
individual becomes symptomatic or eventually, the 
dementia syndrome manifests (2, 3). Increasingly, we are 
exploring AD processes at earlier disease stages through 
examining at-risk populations in mid-life which helps 
identify the earliest manifestation of declining brain 
health. In the absence of pharmacological interventions, 
it is estimated that approximately 40% of dementia 
cases could be prevented by targeting epidemiologically 
derived modifiable risk factors (4). Changes occurring 
years earlier than dementia develops have been 
observed in at-risk populations using exploratory and 
sensitive computerised tests assessing e.g. allocentric 
and egocentric spatial processing (5). These test results 
correlate with brain imaging findings in hippocampal 
subfields known to be sensitive to amyloid derived 
neurotoxicity (6); as well as in changes to brain β-amyloid 
in at risk populations aged between 63-81 years old who 
did not have dementia (7). 
Whilst there are global initiatives focusing on dementia 
prevention through risk factor modification (8, 9), there 
remains  a major and complementary need for effective 
AD pharmacological interventions. Irrespective of the 
type of intervention to reduce incident dementia rates, the 
fact is that these studies will engage at risk populations 
who will be, to the most part, in mid-life and healthy. 
Currently, there are 31 AD drugs being tested in Phase 
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III clinical trials (19 of which are disease modifying) (10). 
We argue that using outcome measures assessing clinical 
symptoms and functioning in earlier disease stages is 
less valid than biological measures of disease and what 
the individual considers personally meaningful from 
a treatment. A treatment’s success should therefore be 
determined not only by the impact on the individual’s 
disease (as evidenced by biomarker change) but also by 
its effect on related well-being (as measured by patient 
reported outcomes).
To this end, whilst it is currently proposed by 
regulators that AD trials measure cognition as the 
primary outcome, as trials move to an earlier disease 
stage it could be argued that many commonly used 
(cognitive) measures lack ecological validity and are not 
sensitive enough to detect changes in the earlier stages of 
the AD continuum where the ideal intervention should 
take place (11). Moreover, it is recommended by both 
the US Food and Drug Administration (FDA) (12) and 
European Medicines Agency (EMA) (13) that AD trials 
incorporate measures which capture clinically meaningful 
results to the individual. Patient reported outcome 
measures (PROMs) are  developed for  the incorporation 
of the person’s own perspective regarding their treatment, 
though these measures are currently not used in AD 
clinical trials (14). PROMs reflect an individual’s view on 
what they define as an effective treatment and consider 
a meaningful change. Notably, PROMs are already 
more widely used in other disease areas. For example, a 
recent study of nearly 100,000 clinical trials published on 
clinicaltrials.gov found that a PROM had been used in 
27% of all trials, primarily in oncology (15).
In light of the drive towards early detection, looking 
at younger at-risk populations and the main regulators’ 
recommendation for clinically meaningful outcome 
measures, we have established the electronic Person 
Specific Outcome Measure (ePSOM) development 
programme. As the target population in dementia 
prevention research is an at-risk population, our 
group took the view that what matters to people when 
developing new treatments for AD is approached by 
way of maintenance of brain health (16, 17). The ePSOM 
programme consists of four sequential steps, ultimately 
aiming to employ new technology to create an outcome 
measure to be used in AD clinical research and practice. 
This will be in the form of an outcome app used on any 
screen-based device which will assess aspects specific to 
the individual using it. At the start of the programme, 
we reviewed literature around PROMs in AD clinical 
trials which informed our focus group study with people 
with memory concerns, healthy volunteers and health 
care professionals (18). The focus group study yielded 
five domains of importance for what matters to people 
about brain health. These domains formed the basis for 
the next stage of the ePSOM development programme. 
In this paper, we report on a large UK-wide population-
based study to understand what matters to people when 
developing new treatments for Alzheimer ’s disease. 
We consider the respondents to the ePSOM study a 
representative population of individuals who may be 
enrolled in dementia primary and secondary prevention 
clinical trials and characterise what matters to people 
about brain health focusing on key demographic groups. 
Methods
We designed and ran a UK-wide population-based 
online study collecting primarily free text answers (see 
Appendix 1). The study built on a previously run focus 
group study which yielded five domains of importance 
about brain health. The study obtained ethics approval 
from the ACCORD Medical Research Ethics Committee 
in Edinburgh, Scotland. The ePSOM study ran from Aug 
2019 – Dec 2019 and was divided into sections, starting 
with an introductory video and informed consent. 
Free text answers were collected across five pre-defined domains. These answers 
were clustered, leading to specific themes of what matters to people about brain 
health
The study was open to anyone over the age of 18 and 
was launched primarily via Alzheimer’s Research UK 
media channels through e-mails to individuals registered 
on their mailing lists and a social media campaign 
(with social media support from other dementia related 
organisations). We collected key sociodemographic and 
clinical data such as having been seen by a doctor because 
of any brain health issues though the primary method 
of the survey used a qualitative approach. Respondents 
were presented with the five domains derived from the 
earlier focus group work to orientate and channel free text 
responses: [1] Everyday functioning; [2] Sense of Identity; 
[3] Relationships and Social Connections; [4] Enjoyable 
Activities and [5] Thinking problems. They were then 
asked to provide free text answers on what they would 
like to retain or keep being able to do in those domains 
if their brain health got worse. At the end of the study, 
respondents were asked to identify five answers across all 
the answers they had given which they consider the most 
important. We used Natural Language Processing (NLP) 
techniques to analyse the free text data (see Figure 1).
Figure 1. Natural Language Processing techniques used 
to analyse the survey data
3
JPAD  - Volume
Step 1: Natural Language Processing to create 
clusters
We used NLP to create clusters of semantically similar 
free text answers. These clusters were then manually 
annotated with appropriate labels. We refer to the finally 
labelled clusters derived from this stepped NLP-manual 
annotation process as “themes”.  
NLP employed word embeddings trained on 
vast amounts of text data to achieve fine-grained 
representation of semantic regularities in text. We 
were thus able to build robust representations of free 
text answers. To begin, “stop words” (i.e. words that 
occur very frequently and contribute little to semantic 
content) and punctuation were removed from the free 
text answers.  The resulting texts were then converted to 
numerical vector representations by using GloVe vectors 
(19) to generate sentence embeddings. These vectors 
encode semantic relationships between words and can be 
used to cluster semantically similar text segments. This 
allowed us to use automated methods to identify words, 
and thus answers, of a similar “theme” or meaning. The 
K-means clustering algorithm was used to cluster the 
answer embeddings within each of the five domains. The 
K parameter, that is, the desired number of automatic 
clusters per domain, was determined analytically. The 
goal was to generate fine grained clusters which contain 
semantically similar answers while avoiding overfitting 
or creating so many clusters that important themes are 
not revealed. We found when the number of important 
items in the largest cluster changes by less than 10, 
between each of the previous five increments of K, that 
the majority of the clusters also exhibited minor changes 
in the number of important items. Using this criterion, 
we chose a value of 151 clusters across all five domains. 
This method resulted in a total of 755 clusters of free text 
answers, or 151 clusters for each of the five domains.
Step 2: Manual Annotation to create themes
The clusters that emerged within each of the five 
domains were reordered so that semantically similar 
clusters appeared close together. This was achieved using 
hierarchical clustering on the cluster centroids. We used 
the reordered clusters for manual annotation in each of 
the five domains. Each cluster was represented by the 
200 most frequent unique answers, after punctuation 
and stopwords were removed. The annotation goals 
were to combine any clusters which fit together, exclude 
uninterpretable clusters and label the final clusters thus 
deriving the final themes. Six authors of the current paper 
annotated two domains each, ensuring two separate 
people analysed a single domain, which helped ensure 
inter-rater reliability between domains. Finally, two of the 
authors did quality control across the five domains and 
homogenised the labels across domains. 
Statistical analyses
In this paper, we focus our analyses on key 
demographic groups: age (up to the age of 64 / age 
65 and older); gender (men / women) and education 
(no degree / degree and higher). We present the largest 
themes for each of these demographic groups as well as 
themes which were identified as particularly important 
most often in the final question on the study forms. 
For both of these analyses, we report percentages for 
each theme by key demographic groups. As the 
demographic groups are unbalanced in terms of the 
number of respondents we use percentages rather than 
the absolute number of answers in the statistical analyses. 
The percentages are derived by dividing the count of 
answers within the demographic group by the total 
number of answers in that demographic group, thus 
providing proportions for comparison when dealing 
with imbalanced demographics. It should be noted 
that respondents were not bounded by a minimum or 
maximum number of free text answers they could give in 
each domain. 
Finally, we conducted a Chi-squared test to analyse 
whether the differences in percentages between 
demographic groupings’ answers within each theme were 
statistically significant. A p-value of <0.01 was used in 
statistical significance testing.
Results
The study was completed by 5,808 people from 
across the UK. They provided a total of 82,514 free text 
answers. These were clustered using automated NLP 
techniques resulting in 151 clusters in each of the five 
pre-defined domains, a total of 755 automated clusters 
across all domains, as described. Subsequent analysis 
reduced the number of clusters to 334 (due to a cluster 
being represented in two or more domains) which were 
all manually annotated by the research team. Many 
of the same themes emerged from different domains 
(e.g., the theme of Walking in the “Enjoyable activities” 
domain as well as the “Everyday activities” domain). 
After merging themes with the same label in different 
domains, the final number of unique themes was 184. 
Some respondents used more generic language (e.g., 
“Maintaining independence”) whereas others were 
more specific (e.g., “Driving”). Using NLP methods 
for free text analysis means that, in this example, the 
“Maintaining independence” theme contains 1100 
answers, most containing either the word “independent” 
or “independence”. Analytically, this is therefore not a 
general theme for answers which relate to the concept 
of independence, but a cluster of answers in which 
the respondents are directly referencing the word 
independence as something which is important for them 
to maintain. This has therefore resulted in themes which 
are more or less specific but directly reflect the language 
used by the respondents.
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Pre-defined answers: Characteristics of the 
ePSOM survey sample
The characteristics of the 5,808 respondents are 
presented above (see Table 1). 
Free text answers: An analysis of important 
themes by key demographics
We used NLP techniques and manual annotation to 
group individual free text answers into clusters and then 
themes respectively. The most frequent themes across all 
demographics were reading, driving, friendships and 
following a storyline (Figure 2). We also calculated the 
proportion of answers within each key demographic, 
expressed as percentages of the total answers given by 
that demographic group.
At the end of the survey, respondents were asked to 
identify the five most important answers to them across 
all their answers. We used this metric to rank the themes 
in terms of being selected as particularly important and 
observed a subtle difference between the largest themes 
(themes mentioned the most frequently) and themes 
which are identified as the most important. The 5 top 
important themes across all demographics were family 
connections,  driving, socializing, reading and friendships 
(Figure 3).
Cross-Tabulations of key demographics
The following tables show statistically significant 
proportional differences in theme sizes (Table 2) and 
identifying themes as particularly important (Table 3), 
focusing on demographic group dyads (younger vs 
older; men vs women; individuals with no degree vs 
individuals with a degree or higher).
Table 2 Top 10 themes selected as particularly 
important which had the highest Chi square values 
representing greater differentiation between demographic 
groups by age (younger/older); gender (male/female) 
and education (no degree / degree and higher). A full list 
of particularly important themes which were significantly 
different across key demographics can be found in 
Appendix 4.
Discussion
Building on the scientific foundation provided by 
previous stages of the ePSOM research programme, 
we designed and ran a nationwide study with open 
ended questions to derive free text answers exploring 
what matters to people about maintaining their brain 
health within five focus group-derived domains. To our 
knowledge, this is the first study collecting free and 
systematically analysing text responses from a very large 
number of respondents on what is important to them 
about brain health. The themes and granularity derived 
Table 1. ePSOM survey respondent characteristics
ePSOM survey characteristics
N 5808
Male 1331 (23.1 %)
Female 4463 (76.9%)
Age Mean: 58.6 (SD=13.8) 
Work status Retired                                                                              2105 (36.2%)
Working                                                       1537 (26.5%)
Part time paid work                                                         767 (13.2%)
Self-employed                                                                  397 (6.8%)
Other (includes volunteering) 1002 (17.2%)
Education Degree 2303 (39.7%)
Postgraduate degree                                                                 1380 (23.8%)
High school                                                   971 (16.7%)
Marital status Married              3684 (63.4%)
Single                969 (16.7%)
Divorced         630 (10.8%)
Ever supported a relative, friend or neighbour with dementia? Yes                                                                              4281 (73.7%)
                                                    No    1453 (25.0%)
Anyone assist in completing the survey? No                                                                              5734 (98.7%)
Yes 74 (0.03%)
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from our study are in line with the FDA’s guidance for 
capturing aspects relevant to AD research participants 
“e.g., [assessing] facility with financial transactions, 
adequacy of social conversation” (12).
As AD drug development moves to an earlier phase 
of the neurodegenerative disease spectrum and clinical 
research targets an earlier, younger population, it is 
crucial any outcomes are meaningful and relevant to 
that trial population. Additionally, as upcoming AD 
treatments are hoped to be disease modifying rather 
than reducing symptoms, the cognitive domains which 
respond to the medication may not be the same as with 
symptomatic treatments measured at a later disease stage 
(20). We also know from a recent review that lifestyle 
factors may influence brain health in midlife (21) so it is 
apposite to examine what matters to people about brain 
health including lifestyle dependant factors as this will 
be increasingly relevant in Brain Health Clinics which are 
developing throughout the UK (16) and Europe (17).
There has been other work collecting evidence on 
important outcomes focusing on the point of view 
of people living with dementia (22). The focus of the 
Figure 2. What matters to people about brain health? The survey received 82,514 free text answers which were clustered 
into 184 themes 
This figure shows themes which were mentioned the most, broken down by key demographics. Full figure of the survey themes in Appendix 2.
Figure 3. What matters to people about brain health?  
This figure shows themes with the highest number of answers selected as particularly important by key demographics. Full figure of themes with the most important 
answers in Appendix 3.
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ePSOM programme though is the maintenance of brain 
health. As the majority of the individuals in our study 
had not received a diagnosis of neurodegenerative 
disease, the findings from our study provide evidence 
for what matters to people about brain health in 
normal lived experience which may include people at 
the earlier (asymptomatic) stages of disease rather than 
once the dementia syndrome develops. Our findings 
are supported by literature recognising that AD trials 
currently do not measure outcomes which are relevant 
to the patient themselves. Tochel et al. (23) carried out 
a literature review extracting data from studies where 
participants described outcomes which matter to them. 
Their review concluded by demonstrating an array of 
outcomes which are not commonly captured in clinical 
trials of new treatments (23). 
Changes at the early stages of the AD continuum 
are currently detected by biomarker assessments, with 
functional measures used increasingly towards the more 
symptomatic and advanced stage of the continuum where 
ultimately impairment is evidenced in basic activities of 
daily living. However, dementia prevention cohorts have 
found differences in more than just biomarker assessed 
pathology, e.g. there is evidence that middle-aged adults 
at risk of dementia have poorer cognitive performance, 
principally in visuospatial functions (24) and memory 
(25). Lau et al. (26) concluded that observing early 
functional limitations at baseline in the at-risk population 
had prognostic value in identifying older adults at risk for 
developing functional disability a few years later (26).
Table 2. Top 10 themes selected as particularly important which had the highest Chi square values representing greater 
differentiation between demographic groups by age (younger/older); gender (male/female) and education (no degree 
/ degree and higher)










Mix Board Games and Cards √ 29
Personal Hygiene √ 25
Pets √ 21







Personal Hygiene √ 27
Maintain Independence √ 23
Water Sports √ 18
Concentrate and Understand Books √ 18
Music √ 17
Driving √ 42




Going on Holidays √ 10
Remember Love √ 10
Family Connection √ 10
Give Advice √ 10
Sports √ 8
Full list of particularly important themes which were significantly different across key demographics in Appendix 4.
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A recent review also concluded that in the pre-
dementia stages of AD, executive functions (such as 
inhibitory abilities), attentional and visuospatial functions 
can already be impacted (27). A PROM therefore could be 
viewed as an ecologically valid instrument for cognitive 
assessment measures which are proxies for what matters 
to people, especially if the PROM relates to a cognitive 
process affected early in the course of AD (e.g. activities 
requiring planning, judgement or navigation/orientation 
like confidence driving). The key questions here is: if 
an individual’s score changes on a particular domain 
using a cognitive assessment measure, does this correlate 
with a change of score in a PROM and is therefore a 
change meaningful (by definition) to the patient? While 
functional or Activities of Daily Living scales measure 
a more direct or practical effect a drug may have, these 
measures have limitations such as poor psychometric 
properties (28) and as evidenced by the analysis of key 
demographic groups in the ePSOM survey, what matters 
to people about brain health and their function is different 
depending on age, sex and education levels. By capturing 
data specific to the individual who in effect derives their 
own outcome measure, the ePSOM app in development 
would present an outcome measure for clinical trials 
that captures changes noticed by and meaningful to 
the person themselves and therefore more likely to be 
correlated to their own specific functional outcomes than 
generic outcomes which were derived by homogenising 
population level data. Ultimately, employing more 
meaningful, ecologically valid and sensitive measures 
will facilitate more drugs to be approved by regulatory 
bodies which will actually impact on well-being and 
Table 3. Top 10 largest themes which had the highest Chi square values representing greater differentiation between 
demographic groups by age (younger/older); gender (male/female) and education (no degree / degree and higher)











Laughter and Fun √ 46
Golf √ 44
Make People Laugh √ 44





Sport Watching √ 96
Fishing √ 81
Rational Thinking √ 55
Shopping √ 53




Walk Dogs √ 30
Family Connection √ 28
Play Musical Instruments √ 25
Shopping √ 23
Music √ 20
Discuss Literature and Science √ 19
Use Technology √ 19
Traveling √ 19
Full list of largest themes which were significantly different across key demographics in Appendix 5.
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not just impact on cognition and function ‘on average’ 
between groups (29). Moreover – ePSOMs are immune 
to cultural, educational and language variability as 
each outcome is unique to that individual and bears no 
reference to an external ‘population norm’. 
We used an online study design as it was important 
to allow for free text answers and reach a large number 
of people. However, this is also a limitation in the study 
leading to inevitable sampling bias of individuals who 
are able to access an online survey. There was also a 
demographic imbalance among the survey respondents 
with reference to the UK population as a whole, but 
appropriate analysis focusing on proportions rather than 
absolute values of this relatively large sample mitigates 
the effects of the imbalances in the data. The main 
strength of the study was collecting free text answers and 
using NLP techniques in the data analysis. Employing 
NLP techniques to gather evidence for what outcomes 
matter in AD drug development is unique and we are 
not aware of any similar studies. Free text answers offer 
insights which go beyond rating themes on a scale which 
have been predefined as important by the researchers 
and are culturally biased and limited. Moreover, the open 
character of the questions may motivate respondents to 
reveal more (31). In some regards, our study results may 
be considered comparable to hundreds of focus group 
studies, though by using NLP techniques, we are able 
to extract patterns in answers by key demographic at 
a scale and level of detail not feasible using traditional 
qualitative methodologies. 
Conclusion
There is a growing consensus that PROMs should be 
used in AD trials so that the patient can assess if they 
observe a change in their well-being which is meaningful 
and specific to them. Including the patient’s perspective 
is also recommended by regulatory bodies such as the 
EMA with whom we collaborated in the initial phases 
of this project, and the FDA. In our study, we included 
a large number of people collecting free text responses 
to understand what matters to people about their brain 
health – our analyses focussed on key demographic 
groups. This approach is novel in so much as it uses 
NLP approaches to create a range of outcomes from a 
theoretically limitless range of possible responses and 
then can apply these into quantifiable and ecologically 
valid outcomes. The main criticism and in many ways 
fatal flaw of current approaches to PROMs is that they 
are derived at a population level and therefore have to 
incorporate the characteristics of the population they 
were derived from. These populations will hold certain 
language, cultural and ethnic characteristics making their 
use in other limited in other populations. The ePSOM 
app will ultimately be used by people in earlier stages 
of neurodegenerative disease before dementia develops 
in populations across the globe, in clinical trials with 
seamless translation into clinical practice.
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